Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Padmanee Sharma

Showing results (81-90 of 216) with videos related to

Pageof 22
Sort By:
Immunity|March 31, 2019
Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell StatesSpencer C Wei, Roshan Sharma, Nana-Ama A S Anang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trialBradley C Carthon, Jedd D Wolchok, Jianda Yuan, et al.
The Journal of Clinical Investigation|June 16, 2018
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapySangeeta Goswami, Irina Apostolou, Jan Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 16, 2019
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicitiesSalahaldin A Tahir, Jianjun Gao, Yuji Miura, et al.
Oncotarget|March 19, 2024
Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancerHaven R Garber, Sreyashi Basu, Sonali Jindal, et al.
Cell|August 15, 2017
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeSpencer C Wei, Jacob H Levine, Alexandria P Cogdill, et al.
Journal for Immunotherapy of Cancer|February 5, 2024
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)Margaret Callahan, Asim Amin, Frederic J Kaye, et al.
Cancer Immunity|December 19, 2003
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancerPadmanee Sharma, Sacha Gnjatic, Achim A Jungbluth, et al.
Nature|May 5, 2017
Erratum: Effective combinatorial immunotherapy for castration-resistant prostate cancerXin Lu, James W Horner, Erin Paul, et al.
Cancer Immunology Research|August 31, 2019
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated MannerLewis Zhichang Shi, Sangeeta Goswami, Tihui Fu, et al.
Pageof 22

Showing results (81-90 of 216) with videos related to

Sort By:
Pageof 22
Immunity|March 31, 2019
Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell StatesSpencer C Wei, Roshan Sharma, Nana-Ama A S Anang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trialBradley C Carthon, Jedd D Wolchok, Jianda Yuan, et al.
The Journal of Clinical Investigation|June 16, 2018
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapySangeeta Goswami, Irina Apostolou, Jan Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 16, 2019
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicitiesSalahaldin A Tahir, Jianjun Gao, Yuji Miura, et al.
Oncotarget|March 19, 2024
Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancerHaven R Garber, Sreyashi Basu, Sonali Jindal, et al.
Cell|August 15, 2017
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeSpencer C Wei, Jacob H Levine, Alexandria P Cogdill, et al.
Journal for Immunotherapy of Cancer|February 5, 2024
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)Margaret Callahan, Asim Amin, Frederic J Kaye, et al.
Cancer Immunity|December 19, 2003
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancerPadmanee Sharma, Sacha Gnjatic, Achim A Jungbluth, et al.
Nature|May 5, 2017
Erratum: Effective combinatorial immunotherapy for castration-resistant prostate cancerXin Lu, James W Horner, Erin Paul, et al.
Cancer Immunology Research|August 31, 2019
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated MannerLewis Zhichang Shi, Sangeeta Goswami, Tihui Fu, et al.
Pageof 22